Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat

被引:6
作者
Lambert, DG [1 ]
Champion, HC [1 ]
Kadowitz, PJ [1 ]
机构
[1] Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA
关键词
angiotensin; vasoconstrictor responses; angiotensin type 1 receptors; selective and competitive antagonist; U46619;
D O I
10.1139/cjpp-76-2-133
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of the nonpeptide angiotensin II AT(1) receptor antagonist candesartan on responses to angiotensin II were investigated in the hindquarters vascular bed of the cat. Under constant-flow conditions, injections of angiotensin II into the hindquarters perfusion circuit elicited dose-dependent increases in perfusion pressure. Candesartan in a dose of 3 mu g/kg iv decreased vasoconstrictor responses to angiotensin II in a competitive manner. However, at doses of 10-1000 mu g/kg iv, candesartan shifted the dose-response curve to angiotensin II to the right in a nonparallel manner, suggesting a noncompetitive blockade. The inhibitory effects of candesartan on responses to angiotensin II were long in duration, and the AT(1) receptor antagonist had little effect on baseline pressures. Candesartan was without effect on vasoconstrictor responses to norepinephrine, U46619, PGF(2 alpha), and BAY K8644; on biphasic responses to endothelin-1; and on vasodilator responses to acetylcholine. Candesartan significantly attenuated hindquarters vasoconstrictor responses to angiotensin III and IV with a parallel shift at the 3 mu g/kg iv dose and a nonparallel shift to the right at the high dose of the AT(1) receptor antagonist. The results of the present study indicate that candesartan is a potent angiotensin AT(1) receptor antagonist that can induce both competitive and noncompetitive blockade of responses to angiotensin II, III, and IV in the hindquarters vascular bed of the cat.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 43 条
[1]  
BAUER PH, 1991, MOL PHARMACOL, V39, P579
[2]  
BERTOLINO F, 1994, J PHARMACOL EXP THER, V268, P747
[3]   ANGIOTENSIN-II RECEPTOR SUBTYPES - CHARACTERIZATION, SIGNALING MECHANISMS, AND POSSIBLE PHYSIOLOGICAL IMPLICATIONS [J].
BOTTARI, SP ;
DEGASPARO, M ;
STECKELINGS, UM ;
LEVENS, NR .
FRONTIERS IN NEUROENDOCRINOLOGY, 1993, 14 (02) :123-171
[4]   NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS - THE DISCOVERY OF A SERIES OF N-(BIPHENYLYLMETHYL)IMIDAZOLES AS POTENT, ORALLY ACTIVE ANTIHYPERTENSIVES [J].
CARINI, DJ ;
DUNCIA, JV ;
ALDRICH, PE ;
CHIU, AT ;
JOHNSON, AL ;
PIERCE, ME ;
PRICE, WA ;
SANTELLA, JB ;
WELLS, GJ ;
WEXLER, RR ;
WONG, PC ;
YOO, SE ;
TIMMERMANS, PBMWM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (08) :2525-2547
[5]   Analysis of responses to angiotensin I and angiotensin I-(3-10) in the mesenteric vascular bed of the cat [J].
Champion, HC ;
Garrison, EA ;
Estrada, LS ;
Potter, JM ;
Kadowitz, PJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 309 (03) :251-259
[6]  
CHANG RSL, 1990, MOL PHARMACOL, V37, P347
[7]   COMPARISON OF PRESSER RESPONSES TO ANGIOTENSIN-I, ANGIOTENSIN-II, AND ANGIOTENSIN-III IN PULMONARY VASCULAR BED OF CATS [J].
CHENG, DY ;
DEWITT, BJ ;
MCMAHON, TJ ;
KADOWITZ, PJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (06) :H2247-H2255
[8]  
CHIU AT, 1990, J PHARMACOL EXP THER, V252, P711
[9]   IDENTIFICATION OF ANGIOTENSIN-II RECEPTOR SUBTYPES [J].
CHIU, AT ;
HERBLIN, WF ;
MCCALL, DE ;
ARDECKY, RJ ;
CARINI, DJ ;
DUNCIA, JV ;
PEASE, LJ ;
WONG, PC ;
WEXLER, RR ;
JOHNSON, AL ;
TIMMERMANS, PBMWM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (01) :196-203
[10]   NON-PEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS .2. PHARMACOLOGY OF S-8308 [J].
CHIU, AT ;
CARINI, DJ ;
JOHNSON, AL ;
MCCALL, DE ;
PRICE, WA ;
THOOLEN, MJMC ;
WONG, PC ;
TABER, RI ;
TIMMERMANS, PBMWM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 157 (01) :13-21